miocamycin has been researched along with levofloxacin in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hirai, K; Hiramatsu, K; Kishi, K; Murakami, J; Nasu, M; Yamasaki, T | 1 |
| De Vecchi, E; Drago, L; Gismondo, MR; Lombardi, A; Nicola, L; Valli, M | 1 |
| Hiramatsu, K; Hirata, N; Kadota, J; Kishi, K; Murakami, J; Nasu, M; Shibata, T; Yamasaki, T | 1 |
| Bagnardi, V; Botteri, E; Carobbio, A; Corrao, G; Falcone, C; Leoni, O; Zambon, A | 1 |
4 other study(ies) available for miocamycin and levofloxacin
| Article | Year |
|---|---|
Macrolides and clindamycin suppress the release of Shiga-like toxins from Escherichia coli O157:H7 in vitro.
Topics: Animals; Anti-Bacterial Agents; Bacterial Toxins; Cefdinir; Cephalosporins; Chlorocebus aethiops; Clindamycin; Dose-Response Relationship, Drug; Escherichia coli O157; Fosfomycin; Humans; Latex Fixation Tests; Levofloxacin; Microbial Sensitivity Tests; Miocamycin; Ofloxacin; Roxithromycin; Shiga Toxin 1; Shiga Toxin 2; Time Factors; Vero Cells | 2000 |
Bactericidal activity of levofloxacin, gatifloxacin, penicillin, meropenem and rokitamycin against Bacillus anthracis clinical isolates.
Topics: Anthrax; Anti-Bacterial Agents; Anti-Infective Agents; Bacillus anthracis; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Meropenem; Microbial Sensitivity Tests; Miocamycin; Ofloxacin; Penicillins; Thienamycins | 2002 |
Treatment with rokitamycin suppresses the lethality in a murine model of Escherichia coli O157:H7 infection.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Colony Count, Microbial; Disease Models, Animal; Escherichia coli Infections; Escherichia coli O157; Feces; Levofloxacin; Male; Mice; Mice, Inbred C3H; Miocamycin; Ofloxacin; Survival Analysis | 2003 |
Generating signals of drug-adverse effects from prescription databases and application to the risk of arrhythmia associated with antibacterials.
Topics: Adverse Drug Reaction Reporting Systems; Anti-Bacterial Agents; Arrhythmias, Cardiac; Case-Control Studies; Ciprofloxacin; Clarithromycin; Cohort Studies; Community Health Planning; Databases, Factual; Drug Monitoring; Erythromycin; Humans; Italy; Levofloxacin; Miocamycin; Norfloxacin; Ofloxacin; Pharmacoepidemiology; Risk Factors | 2005 |